Sodium metatungstate

Sodium metatungstate (Sodium polyoxotungstate) is a NTPDase inhibitor, with Ki values of 2.58 μM, 3.26 μM, and 28.8 μM for NTPDase 1 (CD39), NTPDase 3 and NTPDase 2 respectively[1]. Sodium metatungstate has anti-inflammatory and anti-cancer effect. Sodium metatungstate inhibits ATP breakdown but also blocks central synaptic transmission[1][2][3][4].

Product Specifications

CAS Number

[12141-67-2]

Product Name Alternative

Sodium polyoxotungstate; POM-1

UNSPSC

12352100

Hazard Statement

H302, H318, H412

Target

Interleukin Related; P2X Receptor; P2Y Receptor; Phosphatase; Pyroptosis

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pom1.html

Concentration

10mM

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

Smiles

[3Na2WO4.9WO3]

Molecular Formula

H2Na6O40W12

Molecular Weight

2986.01

Precautions

H302, H318, H412

References & Citations

[1]Wall M J, et al. The novel NTPDase inhibitor sodium polyoxotungstate (POM-1) inhibits ATP breakdown but also blocks central synaptic transmission, an action independent of NTPDase inhibition [J]. Neuropharmacology, 2008, 55 (7) : 1251-1258.|[2]Pimenta-dos-Reis G, et al. POM-1 inhibits P2 receptors and exhibits anti-inflammatory effects in macrophages [J]. Purinergic Signalling, 2017, 13: 611-627.|[3]Csóka B, et al. CD39 improves survival in microbial sepsis by attenuating systemic inflammation [J]. The FASEB Journal, 2015, 29 (1) : 25.|[4]Yang R, et al. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade [J]. Journal for immunotherapy of cancer, 2020, 8 (1) .